Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer deaths in the United
States. Single-agent gemcitabine remains the standard treatment of advanced pancreatic
adenocarcinoma. A recently discovered histone methyltransferase termed enhancer of zeste
homologue 2 (EZH2) was found to be overexpressed in a variety of carcinomas including
pancreatic adenocarcinoma. Silencing of E-cadherin was proposed as a mechanism by
which enhancer of zeste homologue 2 mediates tumor aggressiveness, and enhancer of …